How TrufaMED prescribes GHK-Cu In the TrufaMED performance medicine program, GHK-Cu is prescribed as injectable subcutaneous peptide therapy, typically in 12-week initial protocols with reassessment at 90 days
10.1523/JNEUROSCI.1607-04.2004 J
Treated areas will be disinfected, and guidelines will be drawn to ensure an even application of the treatment
For example, the chelate formed by ethylenediaminetetraacetic acid (EDTA) with metal ions is tens of thousands of times more stable than that of ammonia, because the chelate ring structure reduces the competitive coordination of solvent molecules and lowers the entropy change of hydration of metal ions
Lee JY, Kang DH, Chung DY, Kwon JK, Lee H, Cho NH, et al